Early cancer screening is crucial because it increases the chances of detecting cancer at an initial stage when it is more likely to respond to treatment, improving survival rates, and enabling potentially curative options. Early-stage detection often allows for less aggressive treatments, reduces healthcare costs, and enhances the quality of life of patients by catching the disease before it progresses to advanced, harder-to-treat stages.
EasyCheck360® is a non-invasive blood test designed to detect cancer early by identifying Circulating Tumour Cells (CTCs). These cells are only found in individuals with cancer and are not present in people with non-cancerous conditions, making this test highly accurate. EasyCheck360® can detect CTCs in almost all types of cancer, including early stages (Stage 0, I, and II), in both men and women.
By providing reliable results, this test helps your doctor make timely and informed decisions about your health, giving you the best chance for early diagnosis and potentially curative treatment.
Usual invasive tissue biopsy for cancer diagnosis can be cumbersome, carries risk for a patient, and sometimes is inaccurate too.
Trublood™ offers a risk-free, accurate, and cost-effective alternative to traditional biopsies for detecting solid and brain tumours. It is a safe method that remains effective even when primary or metastatic cancers are undetectable by conventional means, providing crucial diagnostic insights without invasive procedures.
Trublood™ can avoid pain and anxiety related to traditional biopsies with a non-invasive solution to detect colorectal cancer and cancers of the CNS, lung, breast, pancreas, and prostate.
designed just for you, to help you stay strong in your cancer fight.
Cancer is a genetic disease. Every human being is different and unique, so is his/her cancer. However, the conventional 'standard of care' approaches are based on population studies, which disregard the unique genetic landscape and complex metabolic dynamics of the tumour.
As a result, the patients are at risk of failed therapies or aggressive relapse. It is, thus, imperative that the genetic architecture of the tumour is studied comprehensively before deciding the treatment plan, which has to be personalised to the individual patient and his/her disease.
Datar offers advanced and comprehensive tumour profiling tests that analyse cellular and genetic data to provide personalised and actionable treatment recommendations. These tests ensure that every treatment plan is tailored to your specific cancer profile.
Exacta™ is a comprehensive, in-depth, integrative, cellular, and molecular tumour analysis that parses millions of data points to present actionable vulnerabilities of the tumour for effective treatment strategies.
Celldxprovides deep genetic analysis of a tumour, offering insights into key alterations that can guide personalised treatment to 'target' only cancer cells in your body without affecting the normal cells or to stimulate or suppress your 'immune system' to help your body fight cancer.
Pinaka™ is a non-invasive blood test that detects Circulating Tumour Cells (CTCs) from your bloodstream, providing crucial insights to guide cancer treatment. Using advanced techniques like immunocytochemistry (ICC) and FISH, Pinaka™ analyses key biomarkers to match you with the most effective therapies. With just a quick blood draw, this test offers accurate and reliable information comparable to traditional tumour tissue testing, making cancer care safer and more personalised.
Chemoscale™ provides blood-based analysis of tumour cells to guide you on which chemotherapy drug will work for you and to predict resistance to any chemotherapy drug.
For a safe and non-invasive cancer diagnosis, think Cancertrack™
Click to view Trucheck Intelli FAQs.
It eliminates the need for radiation, hospitalisation, anaesthesia, or painful biopsies, providing a safer and more efficient way to track how your cancer responds to therapy and to monitor further progression.
By combining personalised tumour-informed detection and broad tumour-agnostic profiling, it helps your doctor monitor your health, detect relapse early, and tailor treatment to your unique needs. This test provides ongoing insights to ensure better outcomes and timely care.
KNOW MORE
It eliminates the need for radiation, hospitalisation, anaesthesia, or painful biopsies, providing a safer and more efficient way to track how your cancer responds to therapy and to monitor further progression.